Advertisement

Topics

$AGIO FDA Acceptance of sNDA for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy. Pdufa June 21, 2019

07:02 EST 20 Feb 2019 | Odi Bruckman

FDA Acceptance of sNDA for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy. Pdufa June 21, 2019

Original Article: $AGIO FDA Acceptance of sNDA for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy. Pdufa June 21, 2019

NEXT ARTICLE

More From BioPortfolio on "$AGIO FDA Acceptance of sNDA for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy. Pdufa June 21, 2019"

Advertisement
Quick Search
Advertisement
Advertisement